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Background: Alcohol has been suggested to be either protective of, or not associated with Parkinson’s disease
(PD). However, experimental animal studies indicate that chronic heavy alcohol consumption may have dopamine
neurotoxic effects relevant for PD. We studied the association between diagnosed alcohol use disorders and PD.
Methods: All individuals in Sweden admitted with a diagnosis of an alcohol use disorder or appendicitis (reference
group) between January 1, 1972 and December 31, 2008 were identified through the Swedish National Inpatient
Register, and followed for up to 37 years for a diagnosis of PD. We estimated hazard ratios (HR) with 95%
confidence intervals (CI) and adjusted for age and sex.
Results: We found 1,741 (0.3%) cases of PD in the cohort of 602,930 individuals, 1,083 (0.4%) among those
admitted with an alcohol use disorder and 658 (0.2%) of the individuals admitted with appendicitis. The mean
follow-up time was 13.6 and 17.1 years, respectively. The HR for PD associated with an alcohol use disorder was
1.38 (CI 1.25-1.53) adjusted for age and sex. When the risk was estimated in age groups for first hospital admission
with PD the highest risk was observed in the lowest age group, ≤44, HR 2.39 (0.96-5.93), adjusted for age at
exposure and sex.
Conclusions: A history of an alcohol use disorder conferred an increased risk of admission with a diagnosis of
Parkinson’s disease in both women and men. In particular, the risk seemed higher at lower ages of first admission
with Parkinson’s disease.
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Little is known about the aetiology of Parkinson’s disease
(PD), which is the second most common neurodegenera-
tive disorder following Alzheimer’s disease. It is believed
that major gene mutations cause only a small proportion
of the cases and that environmental factors are involved.
Occupational exposures such as pesticides and herbicides
seem to increase the risk for PD, and possibly lead to dam-
age of dopaminergic cells [1,2].
Alcohol has been suggested to protect from neurode-
generation and vascular disease although the mecha-
nisms are not clear [3]. For instance flavonoids that can* Correspondence: anna-karin.eriksson.2@ki.se
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reproduction in any medium, provided the orbe found in red wine, might have neuro [4] and vascular
protective effects [5]. One review from 2005 came to the
conclusion that there was some evidence for a decreased
risk of PD associated with alcohol consumption, al-
though most studies did not reach statistical significance
[3]. Another review from 2011 states the epidemiological
evidence on these associations to be limited [6]. Even
though there is no association between lower consump-
tion of alcohol and PD, or a modest protective effect, it
is still possible that chronic heavy consumption of alco-
hol could have dopamine neurotoxic effects relevant
for PD, as shown in an experimental animal study by
Gilman et al. [7].
Most previous studies on alcohol consumption and
the risk of PD have used cross-sectional designs, includ-
ing self-report of low to moderate alcohol consumption.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the risk of PD among individuals with heavy alcohol use
or those who would qualify for alcohol abuse or depend-
ence diagnoses. Also, studies investigating the prospect-
ive association between alcohol use disorders and PD
which takes into account the long latency period for de-
veloping PD have not been performed. To our know-
ledge, only one study has investigated the association
between diagnosed alcohol use disorders and PD [8].
This study used the General Practice Research Database
in the United Kingdom and found no association, al-
though had a limited follow-up period.
The aim of this study was to investigate the influence
of alcohol use disorders on the risk for developing PD in
a national-wide study with a long follow-up period. We
prospectively studied in a cohort from the Swedish Na-
tional Inpatient Register, the association between a diag-
nosis of an alcohol use disorder and a diagnosis of PD
up to 37 years later and compared with a population-
proxy group.
Methods
Study population and exclusion criteria
We included all men and women in Sweden who were
hospitalized with either a diagnosis of an alcohol use
disorder or appendicitis between January 1, 1972 and
December 31, 2008, identified through the Swedish
National Inpatient Register. This register is kept by the
National Board of Health and Welfare and covers the
entire Swedish population.
The individuals with an alcohol use disorder (exposed
group), and the individuals with appendicitis (popula-
tion-proxy reference group), were followed with regard
to a diagnosis of PD (see disease classifications below),
recorded in the Swedish National Inpatient Register up
to 2008, i.e. a maximum follow-up of 37 years. Informa-
tion about deaths was obtained from the National Cause
of Death Register through record linkage of the cohort
using the individually unique personal identification num-
bers. Individuals were excluded if they belonged to one or
more of the following groups: 1) had been hospitalized
with a diagnosis of PD prior to or concurrent with admis-
sion for an alcohol use disorder or appendicitis, n = 630;
2) had been hospitalized with a diagnosis of Parkinsonism
(diagnostic codes ICD-8: 342.08 and 342.09, ICD-9: 332B
and 333A-X, or ICD-10: G21-G26) prior to or concurrent
with admission for an alcohol use disorder or appendicitis,
n = 146; 3) had been hospitalized with a diagnose for sub-
stance abuse other than alcohol, i.e. admitted with ICD-8,
ICD-9 and ICD-10 amphetamine-related codes: 304.60,
304E, 969H, F15.0-F15.9, T43.6, n = 7083; cocaine-related
codes: 304.40, 304C, F14, T40.5, n = 441; or opioid-related
codes: 304.00, 304.10, 304A, 965A, F11, T40.0, T41.0,
T40.2, n = 2642. After exclusions, the study comprised276,527 individuals with an alcohol use disorder (73,794
women and 202,733 men) and 326,403 individuals with
appendicitis (149,233 women and 177,178 men).
The study was approved by the Stockholm Regional
Ethical Review Board, Sweden.
Classification of alcohol exposure
Each individual was considered to be exposed from the
time of his or her first admission with a diagnosis of an
alcohol use disorder recorded in the Swedish National
Inpatient Register during the study period. Survival time
was calculated as the interval between this date and the
date of first admission with PD, administrative censoring
on 31 December 2008, or as recorded in the National
Cause of Death Register, whichever came first. The cri-
teria for assignment to the cohort with alcohol diagnoses
were: ICD-8: 291.00-.99 (Alcohol psychosis), 303.00-.99
(Alcoholism); ICD-9: 291A-X (Alcohol psychoses), 303
(Alcohol addiction), 305A (Misuse of alcohol), 980A-X
(Toxic effect of alcohol); ICD-10: F10.0-9 (Psychiatric
disorders caused by alcohol), F10.0-.9 (Psychiatric and
behavioral disorders caused by alcohol), T51.0-9 (Toxic
effect of alcohol), X45 (Unintentional intoxication with
and exposure to alcohol).
Classification of PD
First admission with a diagnosis of PD registered in the
Swedish National Inpatient Register was defined accord-
ing to the Swedish version of the eighth (ICD-8), ninth
(ICD-9) and tenth (ICD-10) revisions of the WHO Inter-
national Classification of Diseases, with the following
codes: ICD-8: 342.00; ICD-9: 332A; and ICD-10: G20.
The accuracy of the PD diagnoses in the Swedish Na-
tional Inpatient Register has been reported to be 70.8%
[9]. The cases were identified by the main and up to seven
contributory diagnoses. To be classified as a case, the date
of first admission with PD had to be registered at least
1 year later than the date for admission for an alcohol use
disorder or appendicitis. In the cohort, 9,761 individuals
had been hospitalized for both an alcohol use disorder
and appendicitis at different occasions. These individuals
were analysed as exposed to an alcohol use disorder re-
gardless of which diagnose that appeared first in time.
Population-proxy reference group
Individuals with appendicitis served as the population-
proxy comparison group, given that appendicitis: 1) is a
relatively frequent reason for admission to hospital; 2)
does not appear to be related to PD, alcohol use disorders
or other drug disorders; 3) has been used successfully as a
population-proxy reference group in other studies [10];
and 4) groups drawn from inpatient medical records have
shown to have an incidence of PD not different from that
of the general population [11]. Inclusion criteria for this
Table 1 Number of individuals with a diagnosis of an alcohol use disorder or appendicitis (n = 602,930) in the Swedish
National Inpatient Register 1972–2008, distributed by age and sex
Alcohol use disorders
(n = 276,527)
Parkinson’s disease among individuals
with alcohol use disorders
(n = 1,083)
Appendicitis (n = 326,403) Parkinson’s disease among
individuals with appendicitis
(n = 658)
Women (%) Men (%) Women (%) Men (%) Women (%) Men (%) Women (%) Men (%)
Total 73,794 (100) 202,733 (100) 208 (100) 875 (100) 149,233 (100) 177,178 (100) 271 (100) 387 (100)
Age
≤29 24,691 (33.5) 43,737 (21.6) 0 0 89,676 (60.1) 106,762 (60.3) 2 (0.7) 3 (0.8)
30 - 44 20,542 (27.8) 61,904 (30.5) 4 (1.9) 10 (1.1) 26,653 (17.9) 36,070 (20.4) 2 (0.7) 3 (0.8)
45 - 59 18,539 (25.1) 60,109 (29.7) 28 (13.5) 91 (10.4) 16,996 (11.4) 18,952 (10.7) 16 (5.9) 37 (9.6)
60 - 74 7,989 (10.8) 31,377 (15.5) 103 (49.5) 456 (52.1) 11,081 (7.4) 11,527 (6.5) 93 (34.3) 133 (34.4)
≥75 2,033 (2.8) 5,606 (2.8) 73 (35.1) 318 (36.3) 4,827 (3.3) 3,859 (2.2) 158 (58.3) 211 (54.5)
Table 2 HRs and 95% CIs for the association between
alcohol use disorders and Parkinson’s disease in the





n n HRa (95% CI) p-valueb
Appendicitis Reference 326,403 658 1
Alcohol Model 1c 276,527 1,086 2.57 (2.32–2.82) <.0001
Model 2 1.52 (1.38–1.67) <.0001
Model 3 2.42 (2.19–2.67) <.0001
Model 4 1.38 (1.25–1.53) <.0001
aAbbreviations: HRs, hazard ratios.
bTested with 95% significant level.
cModel 1 crude.
Model 2 adjusted for age at exposure.
Model 3 adjusted for sex.
Model 4 adjusted for age at exposure and sex.
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related condition at their index admission (ICD-8 or ICD-
9 codes 540–542; or ICD-10 codes K35-K37 identified by
the main and up to seven contributory diagnoses); 2) no
prior, concurrent, or subsequent indication of any alcohol-
or other drug-use diagnoses.
Data analysis
Cox regression analysis was used to calculate hazard ra-
tios (HR) with 95% confidence intervals (CI) for the as-
sociation between a diagnosis of an alcohol use disorder
and later PD. Outcome was first admission with a diag-
nosis of PD. Also, we assessed the risk by age at first ad-
mission for PD. We ran the analyses both with and
without adjustments for sex and age at first admission
for an alcohol use disorder or appendicitis. All analyses
were performed in SAS version 9.2 (SAS Institute, Cary,
NC, USA).
Results
We identified 1,741 cases of PD (0.3%) in the total
cohort of 602,930 individuals in the Swedish National
Inpatient Register (Table 1). Of those who had been hos-
pitalized with an alcohol use disorder, 1,083 (0.4%) had
been admitted with PD, 208 women (0.3%) and 875 men
(0.4%). In the population-proxy reference group, i.e. the
individuals admitted with a diagnosis of appendicitis,
658 (0.2%) were later admitted with PD, 271 women
(0.2%) and 387 men (0.2%). For both women and men,
the greatest proportion of cases occurred in individuals
60 years and older at the time of exposure measurement.
The mean follow-up time was 13.6 years for the group
with alcohol use disorders and the mean age at exposure
43.0 years. In the group with appendicitis the mean
follow-up time was 17.1 years and the mean age at ex-
posure 30.0 years.
The crude HR for PD was 2.57 (2.32-2.82) in the indi-
viduals with an alcohol use disorder compared to thereference group (Table 2). Adjustment for sex did not
substantially alter the estimate. However, when age was
adjusted for the HR was 1.52 (1.38-1.67). The final
model including sex and age resulted in a HR of 1.38
(1.25-1.53). When analysed separately, the HR in women
was 1.64 (1.37-1.97) and in men 1.28 (1.14-1.44) adjusted
for age (Table 3). When stratified by age groups at first
hospital admission for PD, the highest HR was found in
those with age ≤44, HR 2.39 (0.96-5.93) (Table 4).Discussion
In this cohort study, heavy alcohol consumption as indi-
cated by an admission with an alcohol use disorder con-
ferred an increased risk of PD in both women and men.
When the HRs were calculated for age groups of first
admission with PD and adjusted for age at exposure and
sex, the influence of alcohol consumption seemed to be
greater at younger PD ages.
Table 3 HRs and 95% CIs for the association between alcohol use disorders and Parkinson’s disease in women and
men in the Swedish National Inpatient Register 1972-2008, n = 602,930
Women Men
Total Parkinson’s disease Total Parkinson’s disease
n n HRa (95% CI) p-valueb n n HRa (95% CI) p-valueb
Appendicitis Reference 149,233 271 1 177,170 387 1
Alcohol Model 1c 73,794 208 2.31 (1.92–2.77) <.0001 202,733 878 2.48 (2.20–2.79) <.0001
Model 2 1.64 (1.37–1.97) <.0001 1.28 (1.14–1.44) <.0001
aAbbreviations: HRs, hazard ratios.
bTested with 95% significant level.
cModel 1 crude.
Model 2 adjusted for age at exposure.
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it is possible that factors associated with an alcohol-
related diagnosis, such as poor nutrition, lower socioeco-
nomic status or occupational exposure to PD-related
toxins, might confound the relation between alcohol use
disorders and PD. In this study we did not have the oppor-
tunity to control for potential confounders other than age.
At the same time, very little is known about which risk
factors are influencing the risk for PD. Notably, we did
not adjust for smoking which is one of few factors that
has consistently been found to decrease the risk for PD
[11]. Thus, since there is a covariation between alcohol
consumption and smoking, the true risk for PD associated
with alcohol consumption in this study might be higher
than our findings. When adjusting the estimates for age,
the HRs were reduced. This can be explained by the differ-
ence in mean age of admission for the two exposure
groups in our study; the mean age of first admission with
an alcohol use disorder was higher. I.e. the group with al-
cohol use disorders was admitted to inpatient care later in
life, although their alcohol abuse most probably have
started much earlier, compared to the group with an ap-
pendicitis, for which patients are admitted immediately,
and at a younger age.
According to our knowledge only one other study has
reported an increased risk of PD associated with alcohol
consumption [12]. Reviews compiling the current know-
ledge on risk factors for PD [3,6] report a modest risk
reduction of PD due to alcohol consumption, or no as-
sociation. The previous literature is very diverse with re-
gard to measurement of alcohol consumption, reference
groups, study populations, ways of diagnosing PD and
case identification. Also, there may have been no possi-
bility of separating diagnoses of Parkinsonism from PD,
or to study individuals with extreme alcohol consump-
tion. The previous studies differ from the present study
with regard to exposure measurement. We used inpatient
diagnoses of alcohol use disorders and our comparison
group was the individuals not having been hospitalized for
an alcohol use disorder, however, could have consumed al-
cohol in different quantities (i.e. they were probably notabstainers). Given that it is likely that the control group
also consume some amounts of alcohol, this would imply
that we might have underestimated the risk.
There are good reasons to think that excessive con-
sumption of alcohol could increase the risk of PD. The
direct effects of alcohol include dopamine release [13].
However, the brain is very sensitive to alcohol and chronic
consumption can cause severe brain damage [14]. It has
been demonstrated that chronic heavy alcohol consump-
tion may have dopamine neurotoxic effects, damaging the
central nervous system extensively, including both regions
of the cerebral cortex and cerebellum, and the substantia
nigra or its dopaminergic projections to the putamen, or
both [7]. It is also possible that alcohol contributes to oxi-
dative stress that may affect the brain [15,16]. However,
we can only speculate about why the influence of alcohol
seemed to be greater at younger PD ages. It could be due
to that the neurotoxic dopaminergic effects of alcohol
might be more dramatically different in the group exposed
to alcohol at a younger age, when the control group has
no or very little dopaminergic deficits.
The strengths of this study include its prospective and
population-based design and that we study alcohol ex-
posure by diagnoses of alcohol use disorders, i.e. we are
measuring excessive consumption and are also avoiding
recall bias from retrospective self-report. The majority of
the previous studies in this area have utilized case–control
designs, which might introduce recall bias of exposure
levels [17]. Present consumption is likely to influence the
report of past consumption, and a recent study found that
individuals with PD decreased their alcohol intake at the
time of diagnosis [18]. Further, ours is a relatively large
study with a follow-up period of a maximum of 37 years.
In addition, we were able to exclude individuals that had
been hospitalized for other drug use, and individuals with
Parkinsonism and PD prior or current to exposure.
Some limitations in our study should be acknowl-
edged. The cases of PD were derived from the Swedish
National Inpatient Register, a data source that has been
shown to be valid for epidemiological studies on PD aeti-
ology [19]. The accuracy of PD diagnoses in the Swedish
Table 4 HRs and 95% CIs for the association between alcohol use disorders and Parkinson’s disease distributed by age of first admission with Parkinson’s
disease in the Swedish National Inpatient Register 1972-2008, n = 602,930
Total
population
≤44 45-59 60-74 ≥75
n n HRa (95% CI) p-valueb n HRa (95% CI) p-valueb n HRa (95% CI) p-valueb n HRa (95% CI) p-valueb
Appendicitis
ref
326,403 10 1 53 1 226 1 369 1
Alcohol
model 1c
276,527 14 2.71 (1.20–6.10) 0.016 119 3.58 (2.59–4.94) 0.0001 559 3.78 (3.24–4.41) <.0001 391 1.67 (1.45–1.93) <.0001
Model 2 2.41 (0.98–5.90) 0.056 1.94 (1.38–2.72) <.0001 2.00 (1.71–2.34) <.0001 1.03 (0.89–1.18) 0.732
Model 3 2.69 (1.17–6.12) 0.020 3.37 (2.42–4.69) <.0001 3.55 (3.03–4.16) <.0001 1.60 (1.38–1.85) <.0001
Model 4 2.39 (0.96–5.93) 0.060 1.84 (1.30–2.60) 0.0006 1.84 (1.58–2.18) <.0001 0.91 (0.78–1.06) 0.226
aAbbreviations: HRs, hazard ratios.
bTested with 95% significant level.
cModel 1 crude.
Model 2 adjusted for age at exposure.
Model 3 adjusted for sex.
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screening study of 35,000 twins, and the positive predict-
ive value for PD diagnoses was found to be 70, 8%. When
the analyses were restricted to only primary diagnoses the
positive predictive value was further improved to 83, 0%,
however this leads to reduced sensitivity [19]. Register in-
formation about outpatient care in hospital-based clinics
in Sweden are available only from 2001. While most treat-
ment for PD occurs in outpatient settings, our outcome
measure captured only the PD cases admitted to hospital.
Nonetheless, prior research has shown that a majority of
individuals with PD are admitted to hospital at least once
within six years of their initial diagnosis [20]. It may be
mentioned that it is possible that the group exposed to
alcohol use disorders is more frequently admitted to hos-
pital care and thereby more likely to be assessed for
neurological disorders such as PD compared to the refer-
ence group of individuals with appendicitis. In that case
we could have over-estimated the risk for PD associated
with alcohol exposure. However, the opposite is also pos-
sible and more plausible, i.e. that the group with alcohol-
related disorders is underrepresented in inpatient care.
We cannot exactly establish the point in time for a PD
diagnosis as we are using inpatient data, since most PD
cases are first detected and diagnosed in outpatient care.
However, we have excluded inpatient cases of PD and
Parkinsonism before, and at the time of admission with
an alcohol related disorder. Also, PD is a typical age-
related disease, usually occurring only after 50 years of
age, while severe alcohol problems usually start much
earlier in the life-span. As a result, reversed causality in
our findings is unlikely. Also, we excluded cases of PD
within one year after first admission with an alcohol use
disorder. Extending this period to up to five years did
not substantially change the estimates (data not shown).Conclusions
We found an increased risk of admission with a diagno-
sis of PD for both women and men with a history of an
alcohol use disorder. Given the high level of excessive
alcohol use in the population, an increased risk of a
serious neurodegenerative disease like PD is of public
health importance.
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